Russia plans to give its first personalized melanoma vaccine to 20 patients by the end of 2026, according to Alexander Gintsburg of the Gamaleya National Research Center of Epidemiology and Microbiology. The announcement points to a limited initial rollout of what has been described as the country's first vaccine aimed at skin cancer.
The update places melanoma treatment at the center of Russia's latest medical research efforts. Because the vaccine is described as personalized, it appears intended to be tailored to individual patients rather than used as a standard one-size-fits-all treatment.
So far, the available report focuses on the timeline and the number of patients expected to receive the vaccine. It does not provide broader details on clinical results, eligibility, or how quickly the program might expand beyond the first 20 cases.
Even with those unanswered questions, the plan signals that Russia is moving its melanoma vaccine project toward real-world patient use on a small scale. If the schedule holds, the first recipients are expected to receive the personalized melanoma vaccine before the end of 2026.
